Fig. 2. Treatment with CZL80 during Day4-7, but not Day1-4 after photothrombosis ameliorates progressive neurological dysfunction.

a Diagram showing the design of the experiments in this figure. CZL80 (10 or 30 mg·kg⁻¹·d⁻¹) or vehicle was intraperitoneally injected daily during Day1-4 or Day4-7, and motor function was measured daily after photothrombosis (PT). b Foot fault of left forelimb in the grid-walking task and (c) Forelimb asymmetry in the cylinder task with CZL80 administration during Day1-4 after PT. d Foot fault of left forelimb in the grid-walking task and (e) Forelimb asymmetry in the cylinder task with CZL80 administration during Day4-7 after PT. All results were represented as means ± SEM (n = 9 per group). Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test, ^*P < 0.05, ^**P < 0.01 and ^***P < 0.001 vs. PT.